✨ Free AI Report
CohBar, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CohBar, Inc.
Company Research

CohBar, Inc.: Business Overview, Financials & Competitive Analysis

CohBar, Inc. is a pioneering biotechnology company that leverages the therapeutic potential of mitochondria-based peptides (MBPs) to develop novel treatments for chronic and age-related diseases....

Analyst-debate audio for CohBar, Inc.

AskCyborg analysts argue the bull and bear cases for CohBar, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company Overview of CohBar, Inc.Product Portfolio of CohBar, Inc.Leadership and Management Team at CohBar, Inc.Financial Overview of CohBar, Inc.Marketing Strategies of CohBar, Inc.Market Overview and Competitors of CohBar, Inc.
Get Interactive Report Freeor start reading below
Live on AskCyborg
2/10Challenged
CohBar, Inc.

CohBar's mitochondrial therapeutic platform was discontinued post-merger, making it a defunct entity of primarily historical biotech interest.

▶︎ Listen to the 90-second analyst debate
Competitors covered:Exelixis, Inc.
2/ 10Challenged

Cyborg Score thesis

CohBar's mitochondrial therapeutic platform was discontinued post-merger, making it a defunct entity of primarily historical...

Read the full analyst-debate transcript →
Industry Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: August 17, 2026
AI-Verified Research
30+ Page Report

Get the Latest CohBar, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

CohBar, Inc. is a pioneering biotechnology company that leverages the therapeutic potential of mitochondria-based peptides (MBPs) to develop novel treatments for chronic and age-related diseases. Founded in 2007, the company has made significant strides in the biotech industry, focusing on innovative solutions to address some of the most challenging health conditions. This comprehensive report delves into CohBar, Inc.’s remarkable story, offering insights into its product portfolio, leadership, financial status, marketing strategies, market overview, sales strategies, technologies, HR practices, corporate responsibility, and future plans.

Company Overview of CohBar, Inc.

Pro stress-test →

CohBar, Inc. specializes in the research and development of mitochondria-based therapeutics. The company’s mission is to harness the power of MBPs to create groundbreaking treatments for conditions such as obesity, type 2 diabetes, cancer, cardiovascular diseases, and fibrotic diseases. CohBar’s innovative approach positions it at the forefront of the biotech industry, driven by a commitment to scientific excellence and patient well-being.

Product Portfolio of CohBar, Inc.

Pro stress-test →

CohBar, Inc.’s product portfolio is centered around its proprietary MBP technology. The company’s lead candidate, CB4211, is undergoing clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. In addition to CB4211, CohBar is actively developing other MBP-based therapeutics targeting a range of chronic and age-related diseases, showcasing the versatility and potential of its technology platform.

Leadership and Management Team at CohBar, Inc.

Pro stress-test →

CohBar, Inc. is led by a team of experienced professionals with deep expertise in biotechnology, pharmaceuticals, and business development. Key members include Dr. Joseph Sarret, CEO, who brings over two decades of leadership experience in the biotech industry; Dr. Ken Cundy, CSO, renowned for his work in drug discovery and development; and Marc Goldberg, Chairman of the Board, who has a rich background in healthcare investment and corporate governance. This leadership team is instrumental in driving the company’s strategic vision and operational excellence.

Financial Overview of CohBar, Inc.

CohBar, Inc. has demonstrated a solid financial performance, with a focus on prudent capital management and strategic investments in its research and development pipeline. The company regularly reports on key financial metrics, including funding rounds, revenue growth, and expenditure, which are critical indicators of its fiscal health and sustainability. Investors and stakeholders can gain a comprehensive understanding of CohBar’s financial status by subscribing to our detailed report.

Marketing Strategies of CohBar, Inc.

CohBar, Inc. employs a multifaceted marketing strategy to promote its innovative therapeutics and attract potential partners and investors. The company leverages digital marketing, industry conferences, scientific publications, and strategic collaborations to enhance its visibility and credibility in the biotech sector. These marketing efforts are designed to communicate the unique value proposition of CohBar’s MBP-based therapies to a global audience.

Market Overview and Competitors of CohBar, Inc.

The biotech industry is highly competitive, with numerous companies vying to develop the next breakthrough treatment. CohBar, Inc. operates in a dynamic market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include companies focused on metabolic and age-related diseases, such as Novo Nordisk, Gilead Sciences, and Intercept Pharmaceuticals. Our report provides an in-depth analysis of the competitive landscape, helping stakeholders understand CohBar’s market positioning.

Sales Strategies of CohBar, Inc.

CohBar, Inc.’s sales strategies are aligned with its goal of advancing its MBP-based therapeutics through the clinical trial pipeline and towards commercialization. The company focuses on building strategic partnerships with pharmaceutical companies, securing licensing agreements, and leveraging its scientific discoveries to attract investment. These strategies are crucial for translating CohBar’s research into commercially viable products.

Technologies Utilized by CohBar, Inc.

At the core of CohBar, Inc.’s innovation is its proprietary MBP technology. This cutting-edge platform enables the identification and development of novel peptides derived from mitochondrial DNA, which have the potential to modulate key biological processes. CohBar’s MBP technology is a testament to the company’s commitment to scientific innovation and its potential to revolutionize the treatment of chronic diseases.

HR Practices at CohBar, Inc.

CohBar, Inc. places a strong emphasis on human resources practices that foster a culture of collaboration, innovation, and excellence. The company is dedicated to attracting and retaining top talent in the biotech industry, offering competitive compensation, professional development opportunities, and a supportive work environment. CohBar’s HR practices are designed to empower employees and drive the company’s success.

Corporate Responsibility of CohBar, Inc.

CohBar, Inc. is committed to corporate social responsibility, with initiatives focused on ethical research practices, environmental sustainability, and community engagement. The company actively supports scientific education and outreach programs, and it strives to minimize its environmental footprint through sustainable operations. These efforts reflect CohBar’s dedication to making a positive impact beyond its scientific endeavors.

Future Plans of CohBar, Inc.

Looking ahead, CohBar, Inc. has ambitious plans to expand its MBP-based therapeutic pipeline and advance its lead candidates through clinical development. The company aims to secure additional funding, forge strategic partnerships, and explore new therapeutic areas where its technology can make a significant impact. CohBar’s future plans are centered around its vision of transforming the treatment landscape for chronic and age-related diseases.


Get the comprehensive report on CohBar, Inc. by subscribing to our service.

What the analysts stress-tested

The top findings that survived the multi-agent debate for CohBar, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when CohBar, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ExelixisOncology therapeuticsSelecta BiosciencesCell and gene therapyForty Seven IncImmuno-oncology

Compare CohBar, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CohBar, Inc. operates in Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger) research →
NEW · MCP server

Ask your AI assistant about CohBar, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CohBar, Inc. and its top competitor on Cyborg Score”
“What did CohBar, Inc. do this quarter?”
“Is CohBar, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does CohBar, Inc. do?+
CohBar, Inc. is a pioneering biotechnology company that leverages the therapeutic potential of mitochondria-based peptides (MBPs) to develop novel treatments for chronic and age-related diseases....
What is CohBar, Inc.'s Cyborg Score?+
CohBar, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CohBar, Inc.'s main competitors?+
Named competitors include Exelixis, Selecta Biosciences, Forty Seven Inc. The full competitive landscape is in the AskCyborg report.
How can I get the full CohBar, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CohBar, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CohBar, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed